fidaxomicin
Sign in to saveAlso known as Dificid, PAR-101, Difimicin, Lipiarmicin, PAR 101, OPT-80, Lipiarrmycin, Tiacumicin B
Fidaxomicin, sold under the brand name Dificid (by Merck) among others, is the first member of a class of narrow spectrum macrocyclic antibiotic drugs called tiacumicins. It is a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis. Fidaxomicin is minimally absorbed into the bloodstream when taken orally, is bactericidal, and selectively eradicates pathogenic Clostridioides difficile with relatively little disruption to the multiple species of bacteria that make up the normal, healthy intestinal microbiota. The maintenance of normal physiolog
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 416459611
- Drug.image
- Fidaxomicin.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Dificid, others
- Drug.DailyMedID
- Fidaxomicin
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- A07
- Drug.ATC_suffix
- AA12
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- Minimal systemic absorption
- Drug.elimination_half life
- 11.7 ± 4.80 hours
via Wikipedia infobox
Research
923 papers- Fidaxomicin versus vancomycin for Clostridium difficile infection.The New England journal of medicine · 2011
- Fidaxomicin.2012
- Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.Medicine · 2024
- PMID 408573872025
- Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites.Antimicrobial agents and chemotherapy · 2024
via PubMed
Wikidata facts
- Mass
- 1056.425
- Has use
- medication
Show 6 more facts
- canonical SMILES
- CCC1C=C(C(CC=CC=C(C(=O)OC(CC=C(C=C(C1OC2C(C(C(C(O2)(C)C)OC(=O)C(C)C)O)O)C)C)C(C)O)COC3C(C(C(C(O3)C)OC(=O)C4=C(C(=C(C(=C4O)Cl)O)Cl)CC)O)OC)O)C
- Commons category
- Fidaxomicin
- subject has role
- DNA polymerase inhibitors
- chemical formula
- C₅₂H₇₄Cl₂O₁₈
- isomeric SMILES
- CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)O[C@H]1[C@H](O)[C@H](OC)[C@H](OC/C2=C\C=C\C[C@H](O)/C(C)=C/[C@H](CC)[C@@H](O[C@@H]3OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]3O)/C(C)=C/C(C)=C/C[C@@H]([C@@H](C)O)OC2=O)O[C@@H]1C
- defined daily dose
- 0.4
Sources (7)
via Wikidata · CC0
~6 min read
Encyclopedic overview
6 sectionsContents
- Mechanism
- Biosynthesis
- Clinical trials
- Approvals and indications
- Adverse effects
- References
Fidaxomicin, sold under the brand name Dificid (by Merck) among others, is the first member of a class of narrow spectrum macrocyclic antibiotic drugs called tiacumicins. It is a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis. Fidaxomicin is minimally absorbed into the bloodstream when taken orally, is bactericidal, and selectively eradicates pathogenic Clostridioides difficile with relatively little disruption to the multiple species of bacteria that make up the normal, healthy intestinal microbiota. The maintenance of normal physiological conditions in the colon may reduce the probability of recurrence of Clostridioides difficile infection.
It is marketed by Merck, which acquired Cubist Pharmaceuticals in 2015, and had in turn bought the originating company, Optimer Pharmaceuticals. It is used for the treatment of Clostridioides difficile infection, which is also known as Clostridioides difficile-associated diarrhea or Clostridioides difficile-associated illness (CDI), and can develop into Clostridioides difficile colitis and pseudomembranous colitis.
Excerpted from Wikipedia’s “fidaxomicin” article, available under the CC BY-SA 4.0 licence.